Meloxicam use can result in [[human gastrointestinal tract|gastrointestinal]] toxicity and bleeding, headaches, rash, and [[melena|very dark or black stool]] (a sign of intestinal bleeding). Like other [[NSAID]]s, its use is associated with an increased risk of cardiovascular events such as [[heart attack]] and [[stroke]].<ref>{{cite journal |vauthors=Stamm O, Latscha U, Janecek P, et al |title=Development of a special electrode for continuous subcutaneous pH measurement in the infant scalp |journal=Am. J. Obstet. Gynecol. |volume=124 |issue=2 |pages=193–5 |date=January 1976 |pmid=2012 |doi= |url=}}</ref> It has fewer gastrointestinal side effects than [[diclofenac]],<ref name=hawkey/> [[piroxicam]],<ref>{{cite journal

 
|doi= 10.1093/rheumatology/37.9.946

 
|journal= The British Journal of Rheumatology

 
|volume= 37

 
|pages= 946–51

 
|year= 1998

 
|title= Improvement in gastrointestinal tolerability of the selective cyclooxygenase (COX)-2 inhibitor, meloxicam, compared with piroxicam: results of the Safety and Efficacy Large-scale Evaluation of COX-inhibiting Therapies (SELECT) trial in osteoarthritis

 
|last1= Dequeker |first1= J

 
|last2= Hawkey |first2= C

 
|last3= Kahan |first3= A

 
|last4= Steinbrück |first4= K

 
|last5= Alegre |first5= C

 
|last6= Baumelou |first6= E

 
|last7= Begaud |first7= B

 
|last8= Isomäki |first8= H

 
|last9= Littlejohn |first9= G

 
|last10= Mau |first10= J.

 
|last11= Papazoglou |first11= S.

 
|pmid=9783758

 
|issue= 9

 
|display-authors= 8

 
}}</ref> [[naproxen]],<ref>{{cite journal

 
|journal= Rheumatology

 
|volume= 35, Supplement 1

 
|pages= 22–8

 
|title= A Six-Month Double-Blind Trial to Compare the Efficacy and Safety of Meloxicam 7.5 mg Daily and Naproxen 750 mg Daily in Patients with Rheumatoid Arthritis

 
|last1= Wojtulewski|first1= JA

 
|last2= Schattenkirchner |first2= M

 
|last3= Barceló |first3= P

 
|last4= Le Loët |first4= X

 
|last5= Bevis |first5= PJR

 
|last6= Bluhmki |first6= E

 
|last7= Distel |first7= M

 
|doi=10.1093/rheumatology/35.suppl_1.22}}</ref> and perhaps all other NSAIDs which are not COX-2 selective.<ref name=hawkey>{{cite journal

 
|doi= 10.1093/rheumatology/37.9.937

 
|title= Gastrointestinal tolerability of meloxicam compared to diclofenac in osteoarthritis patients

 
|last1= Hawkey |first1= C

 
|last2= Kahan |first2= A

 
|last3= Steinbrück |first3= K

 
|last4= Alegre |first4= C

 
|last5= Baumelou |first5= E

 
|last6= Bégaud |first6= B

 
|last7= Dequeker |first7= J

 
|last8= Isomäki |first8= H

 
|last9= Littlejohn |first9= G

 
|last10= Mau |first10= J.

 
|last11= Papazoglou |first11= S

 
|journal= Rheumatology

 
|volume= 37

 
|issue= 9

 
|date=Sep 1998

 
|pages= 937–945(9) |display-authors= 8

 
}}</ref> Although meloxicam inhibits formation of [[thromboxane]] A, it does not appear to do so at levels that would interfere with [[platelet]] function.

 


 
A pooled analysis of randomized, controlled studies of meloxicam therapy of up to 60 days duration found that meloxicam was associated with a statistically significantly lower number of [[thrombosis|thromboembolic]] complications than the NSAID [[diclofenac]] (0.2% versus 0.8% respectively) but a similar incidence of thromboembolic events to naproxen and piroxicam.<ref name=Singh>

 
{{cite journal

 
|pmid= 15234645

 
|title= Gastrointestinal tolerability of meloxicam compared to diclofenac in osteoarthritis patients

 
|last1= Singh |first1= G

 
|last2= Lanes |first2= S

 
|last3= Triadafilopoulos |first3= G

 
|journal= Am J Med

 
|volume= 117

 
|issue= 9

 
|year=2004

 
|pages= 100–6

 
|doi=10.1016/j.amjmed.2004.03.012

 
}}</ref>

 


 
Persons with hypertension, high cholesterol, or diabetes are at risk for cardiovascular side effects. Persons with family history of heart disease, heart attack, or stroke must tell their treating physician as the potential for serious cardiovascular side effects is significant.<ref>{{cite web |url=http://www.nlm.nih.gov/medlineplus/druginfo/meds/a601242.html|title=Medline Plus|publisher=Nlm.nih.gov|accessdate=15 November 2014}}</ref><ref>{{cite web |url=http://www.drugs.com/meloxicam.html|title=Drugs.com|publisher=Drugs.com|accessdate=15 November 2014}}</ref>

 

